CME and CFTC Locked in Battle Over On-Chain Perpetual Futures

The US derivatives exchange operator CME Group has found itself at odds with its regulator, the Commodity Futures Trading Commission (CFTC), over the agency's decision to allow blockchain-based perpetual futures products. The CME has sued the CFTC, arguing that these products are harmful to its own futures contracts and that the regulator has mislabeled them, leading to a misapplication of the law. The dispute centers on the fact that perpetual futures, also known as perps, do not have an expiration date, unlike traditional futures contracts. The CME claims that this design feature makes them swaps, which are subject to different regulatory requirements. The CFTC, on the other hand, has approved the listing of perps on platforms such as Kalshi and Coinbase, citing the need to provide a competitive marketplace for these products. The regulator's decision has been met with frustration from some quarters, with critics arguing that it is an attempt to divert attention from the law. The CME's lawsuit challenges the CFTC's approval of perps, alleging that the regulator failed to consider the potential consequences of its decision. The case is currently awaiting federal court action, which could have significant implications for the US approach to the rapidly growing perps market. The CME's stance on perps has been viewed by some as an attempt to protect its own dominance in the derivatives market, rather than a genuine concern about the regulatory framework. The regulator's approach to perps has been characterized as a policy statement, rather than a formal rulemaking, which has raised concerns about the lack of transparency and accountability. As the dispute between the CME and CFTC continues to unfold, it remains to be seen how the US will approach the regulation of perps, and what the implications will be for the broader derivatives market.